Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 21:3:26330040211070298.
doi: 10.1177/26330040211070298. eCollection 2022 Jan-Dec.

Pharmacology update: pamidronate for hypertrophic pulmonary osteoarthropathy in palliative care

Bethany Faust  1 , Aaron Parkinson  2 , Steven J Baumrucker  3
Affiliations
Review

Pharmacology update: pamidronate for hypertrophic pulmonary osteoarthropathy in palliative care

Bethany Faust et al. Ther Adv Rare Dis. .

Abstract

Hypertrophic pulmonary osteoarthropathy (HPOA) is a rare syndrome that causes clubbed fingers, periostitis, and synovial effusions. It can adversely impact a patient's quality of life. It occurs secondary to pulmonary disease - most commonly pulmonary malignancy. The most effective treatment for HPOA is to treat the underlying disease, usually through surgical resection, chemotherapy, or radiation. However, symptomatic treatments rather than definitive treatments (surgical, chemotherapy, or radiation) are more appropriate for the palliative care patient. Pamidronate is a promising medication for the treatment of HPOA for its safety and rapid onset of action. Further research is indicated to determine whether pamidronate is consistently effective.

Keywords: hypertrophic pulmonary osteoarthropathy; pamidronate.

Plain language summary

Hypertrophic pulmonary osteoarthropathy (HPOA) is a rare syndrome that causes pain in the long bones and typical changes in the fingers, called ‘clubbing’. It can adversely impact a patient’s quality of life and occur secondary to lung disease – most commonly pulmonary cancers. The most effective treatment for HPOA is to treat the underlying disease, usually through surgical removal, chemotherapy, or radiation. However, treating the symptoms is often appropriate for the palliative care patient. Pamidronate is a promising medication for the treatment of HPOA for its safety and rapid onset of action. Further research is indicated to determine whether pamidronate is consistently effective.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Pourmorteza M, Baumrucker SJ, Al-Sheyyab A, et al.Hypertrophic pulmonary osteoarthropathy: a rare but treatable condition in palliative medicine. J Pain Symptom Manage 2015; 50: 263–267. - PubMed
    1. Qian X, Qin J. Hypertrophic pulmonary osteoarthropathy with primary lung cancer. Oncol Lett 2014; 7: 2079–2082. - PMC - PubMed
    1. Von Bamberger E. Veränderungen der röhrenknochen bei bronchiektasie. Wien Klin Wochenschr 1889; 2: 226.
    1. Marie P. De l’osteo-arthropathie hypertrophiante pneumique. Rév. Med 1890; 10: 1–36.
    1. Flavell G. Reversal of pulmonary hypertrophic osteoarthropathy by vagotomy. Lancet 1956; 270: 260–262. - PubMed

LinkOut - more resources